HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Michaud, L. B. Search for Related Content PubMed PubMed Citation Articles by Michaud, L. B.

LAURA B. MICHAUD, PHARM.D., is Clinical Pharmacy Specialist, Division of Pharmacy, M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 90, Houston, TX 77030 (lboehnke{at}mdanderson.org).

Purpose. Emerging data from clinical trials on the use of aromatase inhibitors in the management of early-stage, hormone-dependent breast cancer in postmenopausal women are reviewed. Summary. Aromatase is the enzyme responsible for the conversion of androgens to estrogens and the only source of estrogens in postmenopausal women. Clinical trials using aromatase inhibitors in the adjuvant treatment of postmenopausal women with breast cancer are few but significant because of their comparative design with tamoxifen given for five years, long regarded as the gold standard for breast cancer treatment. Data from the Anastrozole, Tamoxifen and Combination trial, the MA-17 trial (letrozole compared with placebo), the Italian Tamoxifen Arimidex trial (anastrozole following tamoxifen), and the Intergroup Exemestane Study have shown promising efficacy and safety in the use of these agents. While the optimal aromatase inhibitor for use in the adjuvant setting has not been elucidated, current evidence-based recommendations include using (1) anastrozole as the first adjuvant therapy for five years, (2) tamoxifen for two to three years, then exemestane or anastrozole for the remainder of the five years, and (3) tamoxifen for five years, then letrozole for another five years. Conclusion. While their impact on survival has not been determined, aromatase inhibitors are slowly changing the management of early-stage, hormone-dependent breast cancer in postmenopausal women because of improved disease-free survival rates. Their ultimate role in therapy is unknown, but educating patients about the potential risks and benefits will allow them to make informed decisions regarding these data and their breast cancer care. Index terms: Aminoglutethimide; Anastrozole; Antineoplastic agents; Breast neoplasms; Clinical studies; Drug comparisons; Drug use; Enzyme inhibitors; Exemestane; Letrozole; Mechanism of action; Patient information; Postmenopause; Protocols; Tamoxifen; Toxicity

 

This article has been cited by other articles:

				K. Gibson and C. L O'Bryant Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors Journal of Oncology Pharmacy Practice, September 1, 2008; 14(3): 139 - 145. [Abstract] [PDF]